nivolumab,ipilimumab
bms
['improve ', '/ipi', 'rcc,(-irccs),(-srcc),(-urcc)', 'nivo', 'nivolumab', 'ipilimumab']
adjuvant nivolumab/ipilimumab does not improve dfs in high-risk rcc #urology #urologist #esmo22
Expert clinical analysis. Practice advice. Policy perspectives.